The mechanism of action is distinctly pleiotropic, targeting both peripheral metabolic pathways and central neurobiology with immense precision. Peripherally, they bind directly to GLP-1 receptors located on pancreatic beta cells to massively stimulate glucose-dependent insulin secretion, while simultaneously suppressing glucagon release from pancreatic alpha cells, thereby potently regulating severe glycemic excursions46. Concurrently, they exert a profound localized effect on the gastrointestinal tract by severely decelerating gastric emptying, physically prolonging postprandial satiety by keeping food in the stomach longer46. Most critically for profound weight loss, these agonists effortlessly cross the blood-brain barrier and bind to GLP-1 receptors heavily clustered within the hypothalamus and brainstem—the central neural epicenters of appetite regulation46. This central binding completely rewires hunger signaling, dramatically increasing feelings of immense fullness, blunting the dopaminergic reward pathways intrinsically associated with food cravings, and driving a highly consistent, involuntary caloric deficit that leads to robust weight loss and major reductions in total cardiovascular risk46.